Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
160.29
-0.21 (-0.13%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
October 04, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
October 04, 2024
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data...
Via
Benzinga
2 Smart Income Stocks to Buy Right Now
October 04, 2024
These storied companies have a lot to offer different investors.
Via
The Motley Fool
3 Industries Set To Explode When Interest Rates Drop
October 03, 2024
Via
Talk Markets
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
Via
Investor Brand Network
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
October 02, 2024
Via
Benzinga
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
September 26, 2024
Via
Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
October 02, 2024
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding...
Via
Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
September 23, 2024
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics.
Via
Chartmill
The Latest Analyst Ratings For Johnson & Johnson
September 19, 2024
Via
Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
September 30, 2024
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by...
Via
Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
September 30, 2024
These 15 dividend stocks can deliver stable passive income for life.
Via
The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
September 28, 2024
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.
Via
The Motley Fool
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
September 27, 2024
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.
Via
Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
September 27, 2024
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory...
Via
Benzinga
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
September 27, 2024
JOHNSON & JOHNSON (NYSE:JNJ) is an undervalued gem with solid fundamentals.
Via
Chartmill
Why Masimo Stock Crushed the Market Today
September 25, 2024
The company seems to be effecting a smooth transition in its leadership.
Via
The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
These dividend players could lift your portfolio no matter what the market is doing.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
September 21, 2024
This healthcare blue chip is making all the right moves to reward shareholders.
Via
The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
September 20, 2024
From
Beasley Allen Law Firm
Via
Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
September 20, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations.
Via
Benzinga
Exposures
Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic...
Via
Benzinga
Exposures
Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
September 19, 2024
This two-step strategy could set investors up with a large sum of passive income in retirement.
Via
The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.